Analytical Data
-
Gene name
CLEC18A
- Application
-
Alternative Names
CLEC18A；MRLP2；C-type lectin domain family 18 member A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A5D8T8
-
Expression Region
27-446aa
-
AA Sequence
EVWPPQLQEQAPMAGALNRKESFLLLSLHNRLRSWVQPPAADMRRLDWSDSLAQLAQARAALCGTPTPSLASGLWRTLQVGWNMQLLPAGLVSFVEVVSLWFAEGQRYSHAAGECARNATCTHYTQLVWATSSQLGCGRHLCSAGQAAIEAFVCAYSPRGNWEVNGKTIVPYKKGAWCSLCTASVSGCFKAWDHAGGLCEVPRNPCRMSCQNHGRLNISTCHCHCPPGYTGRYCQVRCSLQCVHGRFREEECSCVCDIGYGGAQCATKVHFPFHTCDLRIDGDCFMVSSEADTYYRARMKCQRKGGVLAQIKSQKVQDILAFYLGRLETTNEVIDSDFETRNFWIGLTYKTAKDSFRWATGEHQAFTSFAFGQPDNHGFGNCVELQASAAFNWNDQRCKTRNRYICQFAQEHISRWGPGS
-
Molecular Weight
62.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC18A, or C-Type Lectin Domain Family 18 Member A, is a gene that encodes a protein involved in immune response and is particularly associated with the modulation of dendritic cell functions. It is part of the innate immune system and plays a crucial role in pathogen recognition and the subsequent activation of adaptive immunity. Research into CLEC18A has gained momentum due to its potential implications in various pathological conditions, including infections, autoimmune diseases, and cancers. The protein is known to interact with specific carbohydrates on pathogens, facilitating their recognition and promoting phagocytosis. Given its critical role in immune regulation, CLEC18A serves as a promising target for therapeutic interventions aimed at enhancing immune responses or modulating them in cases of autoimmunity. Recombinant forms of the CLEC18A protein are being developed to study its functional properties in vitro and in vivo, elucidating its mechanisms of action and potential as a biomarker or a target for novel treatment strategies. Understanding the structural characteristics and binding affinities of CLEC18A can pave the way for the discovery of new immunotherapeutic agents. The ongoing research on CLEC18A continues to shed light on its significance in immune responses and its potential utility in clinical settings, making it a compelling focus within immunology and therapeutic development. As researchers investigate the roles of CLEC18A in various diseases, its potential applications in improving vaccine responses and designing novel immunotherapies are becoming increasingly apparent.
